May 4, 2016Open Access

Effectiveness and safety of oral HIV preexposure prophylaxis for all populations

Key Points

Key points are not available for this paper at this time.

Abstract

PrEP is protective against HIV infection across populations, presents few significant safety risks, and there is no evidence of behavioral risk compensation. The effective and cost-effective use of PrEP will require development of best practices for fostering uptake and adherence among people at substantial HIV risk.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Fonner et al. (Wed,) studied this question.

synapsesocial.com/papers/69da58160f778bd2e4684b2f https://doi.org/https://doi.org/10.1097/qad.0000000000001145

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement2009 · 63,970 citations
2Bone Disorders in Human Immunodeficiency Virus Infection2003 · 54 citations
3Young key populations and HIV: a special emphasis and consideration in the new WHO Consolidated Guidelines on HIV Prevention, Diagnosis, Treatment and Care for Key Populations2015 · 187 citations
4Bone Mineral Density Changes Among Young, Healthy African Women Receiving Oral Tenofovir for HIV Preexposure Prophylaxis2015 · 50 citations
5Preexposure Prophylaxis for HIV Infection among African Women2012 · 1,617 citations

Bookmark

View Full Paper